The following drug companies made headlines this past week.
1. Philips to acquire Spectranetics devicemaker for $2.2B: 5 things to know
The Dutch healthcare technology company Philips will purchase Colorado Springs, Colo.-based The Spectranetics Corp. for about $2.16 billion.
2. Valeant 'most exposed' to generic competition by FDA's new drug list, says analyst
The Food and Drug Administration on June 27 published a list of more than 200 brand name drugs without generic alternatives on the market. While the list leaves many drugmakers susceptible to more generic competition, Valeant Pharmaceuticals is poised to be hit the hardest.
3. GOP congressman loses $17M on pharma investment: 4 things to know
Congressman Chris Collins, R-N.Y., lost nearly $17 million after stock for an Australian drug company he'd heavily invested dropped by more than 90 percent on June 27.
4. 2 former Ariad Pharma execs charged with insider trading
The Securities and Exchange Commission on June 27 charged three individuals linked to Ariad Pharmaceuticals with insider trading.
5. Hospira recall drives 2 other drug companies to pull injectables from market
Two drug companies that use or repackage Hospira products launched secondary recalls in response to the drugmaker's June 15 recall of several injectable drugs.
6. GSK to stop manufacturing seizure drug Potiga
GlaxoSmithKline will cease production of its seizure drug, Potiga, in mid-2017 due to low patient demand.